Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07463703 · ClinicalTrials.gov registry record · NA
Accelerated Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder
A NA study, sponsored by Cognitive FX.
- Not yet
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT07463703 is a NA study that has not yet begun recruiting, run by Cognitive FX. The registered enrollment target is 15 participants.
The verdict
NCT07463703, a NA study, has not yet begun recruiting, sponsored by Cognitive FX.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study tests a new brain stimulation treatment for post-traumatic stress disorder (PTSD), a condition that affects millions after trauma, causing symptoms like flashbacks, avoidance, mood changes, and heightened alertness. The investigators will enroll 15 adults (ages 18-65) with PTSD. First, participants get a brain scan (fMRI) to map their unique brain connections between areas involved in fear and control-the right amygdala (fear center) and right dorsolateral prefrontal cortex (control area). Using this personalized map, the investigators will apply accelerated transcranial magnetic stimulation (TMS), a safe, non-invasive method using magnetic pulses to adjust brain activity. Treatment lasts 5 days (10 short sessions daily, totaling 90,000 pulses) targeting the identified spot to strengthen control over fear responses. The study checks if this approach is practical, safe (tracking side effects like headaches), and shows early signs of reducing PTSD symptoms (measured by questionnaires and interviews). Follow-up lasts 3 months, with repeat scans to see brain changes. This study will see if personalized, fast-paced TMS targeting the disrupted fear-control brain circuit in PTSD can be feasible and safe, and preliminarily reduce symptoms by improving brain connectivity, potentially offering a quicker alternative to standard treatments.
Interventions
- DEVICE Accelerated functional-connectivity guided transcranial magnetic stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07463703
The ClinicalTrials.gov registry entry for NCT07463703 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cognitive FX, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Accelerated functional-connectivity guided transcranial magnetic stimulation is the first listed.
NCT07463703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07463703 about?
NCT07463703 is a clinical study titled "Accelerated Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder". This study tests a new brain stimulation treatment for post-traumatic stress disorder (PTSD), a condition that affects millions after trauma, causing symptoms like flashbacks, avoidance, mood changes, and heightened alertness. The investigators will enroll 15 adults (ages 18-65) with PTSD. First, p...
What is the current status of trial NCT07463703?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2026-04. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07463703?
The interventions under investigation include: Accelerated functional-connectivity guided transcranial magnetic stimulation (DEVICE).
Who is sponsoring clinical trial NCT07463703?
This trial is sponsored by Cognitive FX, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.